• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

CAR-T

AstraZeneca
Pharma

AZ to build cell therapy supply hub, R&D center in Shanghai

The move positions the British drugmaker as the first multinational pharma company to boast end-to-end cell therapy capabilities in China.
Angus Liu Mar 19, 2026 10:20am
Autoimmune CAR-TNavigating the FDAs new regulatory playbook

Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook

Feb 27, 2026 7:45am
Three blocks displaying from left to right a person a handshake and another person

OXB expands BMS partnership for CAR-T lentiviral vectors

Feb 4, 2026 10:25am
Cellares

Cellares attracts $257M series D to build sites in Japan, Europe

Jan 28, 2026 9:40am
JNJ

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am
BreyanziProductImageforMCL

FDA OKs BMS' Breyanzi as first CAR-T for marginal zone lymphoma

Dec 5, 2025 11:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings